




Patient Engagement at Madrigal

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Christopher Frates

**Vice President, Corporate Communications and
Patient Advocacy, Madrigal Pharmaceuticals**

Disclosure: Madrigal employee



Patient Engagement at Madrigal

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for MASH

- Madrigal developed the first medication for MASH with moderate to advanced fibrosis to receive accelerated approval from the FDA
- Madrigal has worked closely with the MASH patient advocacy community to gather insights about the burden of MASH and support disease education



Photos from an August 2024 Patient Advocacy Summit hosted by Madrigal

Madrigal Organized a Listening Session that Explored Research Priorities for the Patient Community



Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Madrigal Organized a Listening Session that Explored Research Priorities for the MASH Patient Community

What we heard from patient advocates:

- Seek patient input early
- Move away from biopsy
- Improve diversity in clinical trials
 - Extend reach into underserved communities, both rural and urban
- Accelerate research in the pediatric MASH population



Patient Engagement Challenges and Opportunities: Industry Perspective

Challenges

Patient input is valued, but process for collecting isn't always standardized

Patient advocacy function may not exist at smaller companies; may be 'siloe'd' in larger ones

Hard for many patients to attend conferences like The Liver Meeting due to cost of travel

Opportunities

Toolkit to define how and when to collect patient input on a development program

Build a more expansive understanding of patient advocacy's role in biopharma

Establish grants/scholarships to support larger patient presence at medical meetings